Floatz logo

Fezolinetant

Vasomotor Disturbance

Shehzad Basaria, M.D.Small moleculePhase 2Active
CCC
53/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
38/ 100
Competitive Position
95/ 100

Competitive context

10 Active assets in the Vasomotor Disturbance cohort.

Asset / SponsorPhaseRating
Entacapone
Daniel Claassen
Phase 1/2CCC
carbidopa
Daniel Claassen
Phase 1/2CCC
Droxidopa
Vanderbilt University Medical Center
Phase 1/2CCC
Midodrine
Vanderbilt University Medical Center
Phase 1CCC
FDOPA
Daniel Claassen
Phase 1CC

View all 12 →

Same molecule, other indications

Fezolinetant is also rated in:

Hot FlashesDormant
BB
Indicative ·
64 / 100
View asset →
Vasomotor SymptomsDormant
CCC
Indicative ·
53 / 100
View asset →
prostate adenocarcinomaDormant
CCC
Indicative ·
53 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →